“…This result might be explained also referring to our previous studies conducted on diabetic and hyperlipidemic rabbits (Ragazzi et al, 2002), showing that in these pathological conditions, in comparison to normometabolic controls, the degradation of tryptophan is selectively affected mainly at the level of 3-hydroxyanthranilate 3,4-dioxygenase, which is reduced in kidneys, and at the level of aminocarboxymuconate-semialdehyde decarboxylase whose activity is increased in kidneys and liver. The slight increase of the activity of 3-hydroxyanthranilate 3,4-dioxygenase induced by cloricromene in the liver, observed in this study, both in diabetic/hyperlipidemic rabbits and controls, may suggest a protective event through the activation of the metabolic conversion of tryptophan toward NAD + synthesis, which has been indicated as a pivotal keypoint linked to diabetic condition (Okamoto, 2003). However, the opposite effect induced by cloricromene in the kidneys of control animals may suggest complex enzymatic adjustment within the last steps of the kynurenine pathway.…”